Announcements Trials
Browse Landscape

Phase

Phase 2 129Phase 1 127Phase 1/2 91Phase 3 87Phase 2/3 9Phase EARLY_PHASE1 4Phase NA 3Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Melanoma 1Glioblastoma 1

Interventions

Pemetrexed 10Cisplatin 9Erlotinib Hydrochloride 8Carboplatin 7icotinib 5Gefitinib 5Docetaxel 5endostar protein 3Zoledronic Acid 3Radiotherapy 3Paclitaxel 3Gemcitabine 3Endostatins 3Afatinib 3tislelizumab 2pembrolizumab 2osimertinib 2lorlatinib 2flurbiprofen axetil 2dexamethasone 21-phosphate 2atezolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Saline Solution 2Nivolumab 2Drug Therapy 2Dexamethasone 2Chemoradiotherapy 2trametinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all
NCT03715205 2025-08-29

Keynote-593

Merck Sharp & Dohme LLC

Phase 4 Completed
150 enrolled 14 charts
DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03134456 2024-12-03

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Samsung Medical Center

Phase 4 Completed
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡